// App-Quantinova.ai

: Clinical outcomes and late toxicity of hypofractionated intensity-modulated radiotherapy for high-risk prostate cancer.

Researchers

Presenter

  • Michael Wang

Principal Investigators

  • Robert Pearcey

  • Nadeem Pervez

  • Don Yee

  • Alina Mihai

  • Samir Patel

  • John Amanie

  • Matthew Parliament

  • Albert Murtha

  • Sunita Ghosh

  • Marc Mackenzie

  • Colin Field

  • Nawaid Usmani

Medical Centers

  • Division of Radiation Oncology, Cross Cancer Institute

  • Department of Surgery, University of Alberta, Edmonton, AB, Canada

  • Division of Experimental Oncology, Cross Cancer Institute

  • Division of Medical Physics, Cross Cancer Institute

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • NCT00126802

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved